Curemark, a US-based clinical-stage biopharmaceutical company, announced on Thursday that it has named Dr William R McIntyre as its new senior vice president of Global Regulatory Affairs, effective immediately.

Dr McIntyre has held the position of senior vice president of Regulatory Affairs for Endo Par, and managed the approval of four NDAs for Pfizer as associate director of Regulatory Affairs.

Curemark CEO Dr Joan Fallon said, 'I'm excited that Dr McIntyre is onboard as he brings a wealth of regulatory experience to our BLA filing process. He is the right person to lead our regulatory team into the future.'